Background Carriers of APOE ε2 and ε4 have an increased risk of intracerebral haemorrhage (ICH) in lobar regions, presumably because of the eff ects of these gene variants on risk of cerebral amyloid angiopathy. We aimed to assess whether these variants also associate with severity of ICH, in terms of haematoma volume at presentation and subsequent outcome.
Summary
Background Carriers of APOE ε2 and ε4 have an increased risk of intracerebral haemorrhage (ICH) in lobar regions, presumably because of the eff ects of these gene variants on risk of cerebral amyloid angiopathy. We aimed to assess whether these variants also associate with severity of ICH, in terms of haematoma volume at presentation and subsequent outcome.
Methods
We investigated the association of APOE ε2 and ε4 with ICH volume and outcomes in patients with primary ICH in three phases: a discovery phase of 865 individuals of European ancestry from the Genetics of Cerebral Hemorrhage on Anticoagulation study, and replication phases of 946 Europeans (replication 1) and 214 AfricanAmericans (replication 2) from an additional six studies. We also assessed the association of APOE variants with ICH volume and outcomes in meta-analyses of results from all three phases, and the association of APOE ε4 with mortality in a further meta-analysis including data from previous reports. Admission ICH volume was quantifi ed on CT scan. We assessed functional outcome (modifi ed Rankin scale score 3-6) and mortality at 90 days. We used linear regression to establish the eff ect of genotype on haematoma volume and logistic regression to assess the eff ect on outcome from ICH.
Findings For patients with lobar ICH, carriers of the APOE ε2 allele had larger ICH volumes than did non-carriers in the discovery phase (p=2·5×10

Introduction
Intracerebral haemorrhage (ICH) is a severe form of stroke that predominantly aff ects elderly people.
1,2 Despite advances in neurocritical care, more than 75% of patients will die or become severely disabled as a result of their ICH. 3 Eff ective preventive and acute treatments are therefore urgently needed.
The volume of blood that exits the circulation into the brain parenchyma to form the haematoma is the strongest predictor of mortality and functional outcome after ICH. 4 We previously reported that the ε2 and ε4 alleles of APOE are associated with risk of ICH in the lobar brain regions, presumably through their eff ect on risk of cerebral amyloid angiopathy (CAA). 5 CAA accounts for 12-34% of all ICH in elderly people, and seems to have little or no role in ICH that occurs in the deep regions of the brain (ie, basal ganglia, thalamus, or brainstem). 6 Previous histopathological analyses of specimens from individuals with CAA have shown disparate eff ects of the ε4 and ε2 alleles. Carriers of ε4 have an increased number of amyloid-laden vessels, whereas carriers of ε2 have an increase in the proportion of amyloid-laden vessels aff ected by the severe vasculopathic changes that are most often reported in CAA-related ICH. 7, 8 On the basis of these fi ndings, we postulated that lobar haemorrhages occurring in carriers of APOE ε2 would be larger on average than would those occurring in individuals without a copy of the allele. Furthermore, because ε2 should aff ect only CAA and not other forms of cerebral small-vessel disease, we also postulated that ε2 would have no eff ect on haematoma volume in patients with deep ICH. To test these hypotheses, we used the resources of the International Stroke Genetics Consortium (ISGC) to undertake a multicentre candidate gene association study of ICH.
Methods
Study design and patients
We used a three-phase design, with data from participating studies assessed in a discovery phase and two replication phases. In the discovery phase, initial genetic-association analyses of APOE ε2 and ε4 and radiographical (ICH volume) and clinical (mortality and functional outcome) endpoints were done in patients of self-reported European ancestry who were recruited as part of the multicentre Genetics of Cerebral Hemorrhage on Anticoagulation (GOCHA) study in the USA. 9 In the fi rst replication phase (replication 1), we assessed data from patients with ICH who were of self-reported European ancestry provided by International Stroke Genetics Consortium investigators from the following studies: Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS) 10 at the University of Cincinnati in Cincinnati, OH, USA; the Diff erences in the Imaging of Primary Hemorrhage based on Ethnicity or Race (DECIPHER) study 11 at Georgetown University in Washington, DC, USA; the Hospital del Mar Intracerebral Haemorrhage study 12 (HM-ICH) in Barcelona, Spain; the Jagiellonian University Hemorrhagic Stroke Study 13 (JUHSS) in Krakow, Poland; the Lund Stroke Registry 14 (LSR) in Lund, Sweden; and the Medical University of Graz Intracerebral Haemorrhage study 15 (MUG-ICH) in Graz, Austria. In the second replication phase (replication 2), we assessed data for patients of selfreported African-American ancestry with ICH who were recruited in the USA as part of the GOCHA, 9 GERFHS, 10 and DECIPHER 11 studies. Patients were enrolled in these studies according to methods previously published. 5 Briefl y, all included patients had primary ICH and were assessed at participating study centres. Eligibility was restricted to patients who were older than 55 years to reduce the possibility of inadvertent inclusion of individuals with secondary ICH (ie, due to an underlying vascular anomaly). All patients had confi rmation of ICH by neuroimaging (CT or MRI). Exclusion criteria were trauma, brain tumour, haemorrhagic transformation of a cerebral infarction, vascular malformation, or any other cause of secondary ICH.
Recorded clinical characteristics included history of hypertension (clinical diagnosis of hypertension or history of antihypertensive drug use), pre-ICH exposure to warfarin, antiplatelet drugs, or statins, history of ICH in a fi rst-degree relative, and alcohol or tobacco use. Trained study staff interviewed survivors of ICH or their caregivers by telephone at 90 days after ICH to assess functional outcome and mortality with the modifi ed Rankin scale (mRS).
All studies were approved by the institutional review boards or ethics committees of participating institutions, and all participants provided written informed consent for participation in genetic studies.
Procedures
Locations of ICH and measurements of volume were established from admission CT scans. The location was assigned by stroke neurologists at every participating site as previously described. 5 ICH isolated to the cortex (with or without involvement of subcortical white matter) was defi ned as lobar, whereas ICH selectively involving the thalamus, internal capsule, basal ganglia, or brainstem was defi ned as deep (non-lobar). Several concurrent bleeds involving deep and lobar territories were defi ned as mixed ICH, and these individuals were not eligible for inclusion in our analysis. Patients with cerebellar haemorrhages (135 patients) or with CT scans of insuffi cient quality for establishment of location (11 patients) were also excluded from the present study. Disagreement about ICH location assignment was resolved by a group of study neurologists and neuroradiologists by consensus; however, this could not be reached for 35 patients, who were excluded. ICH volume was established in samples from the discovery phase by use of a previously published semi-automated method with high inter-rater agreement. 5, 16 ICH volumes for CT scans in replication phases 1 and 2 were quantifi ed with either semi-automated methods or the ABC/2 method. [10] [11] [12] [13] [14] [15] 17 We assessed agreement between methods in a subset of CT scan), which yielded good correlation (Spearman's r=0·94; p<0·0001).
DNA was isolated from fresh or frozen blood, quantifi ed with a quantifi cation kit (Qiagen, Valencia, CA, USA) and normalised to a concentration of 30 ng/μL. Two genotype-determining variants in APOE, rs7412 and rs429358, were genotyped with two separate assays. 5 Allelic reads from the two assays were then translated to APOE genotypes (ε3ε3, ε3ε4, ε4ε4, ε3ε2, ε2ε2, and ε2ε4).
Genome-wide genotyping of patients with ICH is ongoing within the International Stroke Genetics Consortium, and was available only for patients in the discovery phase and controls without ICH. Genotype data for variants outside the APOE gene have been the subject of an interim analysis, 18 which did not identify any genome-wide signifi cant associations (p<5·0 × 10 -⁸) between common variants and ICH incidence, volume, or outcome. Therefore, we assessed only the association of APOE alleles ε2 and ε4. However, we used genome-wide data to adjust all analyses for population stratifi cation (webappendix pp 1-3).
All personnel who did the genotyping were masked to clinical and neuroimaging data. Data for genotypes and phenotypes were subsequently submitted to the coordinating centre (Massachusetts General Hospital, Boston, MA, USA) for analysis. All patients with ICH were in Hardy-Weinberg equilibrium for APOE genotypes.
See Online for webappendix
Statistical analysis
We assessed associations between APOE ε2 or ε4 and ICH volumes with linear regression in samples from the discovery phase, with lobar and deep ICH analysed separately. ICH volumes at presentation were logtransformed to achieve normality. Multivariate models for all analyses included the following variables: age, sex, pre-ICH history of hypertension, warfarin or antiplatelet drug use at time of ICH, time from symptom onset to CT scan, number of ε2 alleles (0, 1, or 2), number of ε4 alleles (0, 1, or 2), and principal component 1 or principal component 2 derived from genome-wide genotyping data (only available for discovery phase-analyses; webappendix p 1). Analyses for replication phases 1 and 2 were also adjusted for the method used for assessment of ICH volume (ie, semiautomated vs ABC/2). Results from the three stages were combined in meta-analysis by use of a random-eff ects, inverse-variance weighted (DerSimonian-Laird) method.
We tested APOE alleles ε2 and ε4 for association with mortality and poor functional outcome (mRS score of 3-6) at 90 days by use of logistic regression. We analysed lobar ICH and deep ICH separately. Multivariate models (for both discovery and replication) included age, sex, warfarin or antiplatelet drug use at time of ICH, principal component 1 or principal component 2 status (only for discovery-phase analyses), number of ε2 alleles (0, 1, or 2), and number of ε4 alleles (0, 1, or 2). We undertook additional analysis adjusting for ICH volume at presentation as an intermediate variable, because it is a potent predictor of ICH outcome. Finally, results from the three stages were combined in meta-analysis by use of a random-eff ects, inverse-variance weighted (DerSimonian-Laird) method.
For genetic modelling, we reanalysed all data under dominant and recessive models, and compared predictive power for the outcomes of interest with results yielded 10 Diff erences in the Imaging of Primary Hemorrhage based on Ethnicity or Race (DECIPHER), 11 Hospital del Mar Intracerebral Hemorrhage Study (HM-ICH), 12 Jagiellonian University Hemorrhagic Stroke Study (JUHSS), 13 Lund Stroke Registry (LSR), 14 and Medical University of Graz Intracerebral Haemorrhage Study (MUG-ICH). 15 Replication 2 included patients of African-American ancestry enrolled in GOCHA, 9 GERFHS, 10 and DECIPHER. 11 mRS=modifi ed Rankin scale. 
History of hypertension
Univariate and multivariate analyses were adjusted for principal components 1 and 2 (see webappendix p 1) to eliminate possible confounding due to population stratifi cation. Previous studies have reported an association between APOE ε4 and mortality from ICH (irrespective of haemorrhage location). [20] [21] [22] [23] [24] We therefore pooled results from our analyses and from previously published reports in a meta-analysis of the role of APOE ε4 in ICH mortality. We searched the published work for studies that reported the association of APOE with ICH mortality in human beings (webappendix p 6). For studies that overlapped with published reports, only the most recent comprehensive results were included. Data from the present study were analysed irrespective of ICH location to match phenotype defi nition and methods of the original publications, which did not adjust or stratify analysis by lobar or deep anatomical location. We undertook the metaanalysis with a random-eff ects, inverse-variance weighted (DerSimonian-Laird) method.
The signifi cance threshold for analyses of ICH volume, mortality and outcomes, and genetic model comparisons was p<0·05. All analyses were done with The R Project for Statistical Computing, version 2.1.10.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
After application of exclusion criteria and of genotype quality control procedures, 849 patients with lobar ICH and 1176 patients with deep ICH were available for analysis (table 1) . Individuals with lobar ICH were older (p=0·0002), had larger haematoma volume at admission (p<0·0001), and more frequently possessed the APOE ε2 (p=0·0008) and ε4 alleles (p=0·0004) than did individuals with deep ICH. Individuals with deep ICH were more likely to report history of hypertension than were those with lobar ICH (p<0·01). In multivariate analyses, adjusted for age and ICH volume, mortality (p=0·31) and rates of poor outcome (p=0·22) did not diff er between the lobar and deep ICH groups.
We noted an association between APOE ε2 and lobar ICH volume in univariate and multivariate analysis of patients in the discovery phase (table 2) . This fi nding was sequentially replicated in multivariate models for replication phases 1 and 2 (table 3). Our meta-analysis of all available data showed a signifi cant association between APOE ε2 and lobar haematoma volume (ie, p<5·0×10 -⁸). In the meta-analysis, each ε2 copy increased lobar ICH volume by a mean of 5·3 mL (95% CI 4·7-5·9 mL), or about 18% of mean haematoma size at presentation (fi gure).
There was no association between APOE ε4 and lobar ICH volume. Post-hoc power calculations estimated power for discovery of ε4-related increases in lobar ICH 
*Corresponds to a mean increase of 5·3 mL (95% CI 4·7-5·9), or about 18% of average lobar hematoma size at presentation for each copy of the APOE ε2 allele. Table 3 : APOE ε2 and ε4 and intracerebral haemorrhage volumes volume of 1·5 mL or greater (~6% of average lobar haematoma size) to be more than 0·80. In a comparison of linear model fi ts for lobar ICH volume, the additive model provided a better fi t than did the dominant (p=0·006) or recessive (p=0·001) models.
APOE allele variants and ICH volume were unrelated in individuals with deep ICH in the single-phase analyses and in the meta-analysis (table 2 and table 3 ). The statistical power was more than 0·80 to identify increases in deep ICH volume equal to or more than 2·5 mL (~17% of mean deep ICH volume) associated with either APOE ε2 or ε4.
We investigated whether APOE genotype, mediated by its eff ect on ICH volume, aff ected disability and mortality after an ICH. 4 APOE ε2 was associated with poor outcomes and mortality after lobar ICH in the discoveryphase analyses (table 4) and in replication phases 1 and 2 (table 5). Our meta-analyses of all available data confi rmed the signifi cant association between ε2 and mortality and poor outcome (both p<5·0×10 -⁵). To assess whether the reported association between ε2 and ICH outcome was mediated by ICH volume, we repeated all outcome analyses after adjustment for baseline haematoma size. This adjustment negated any association between ε2 and mortality or functional outcome (p>0·20 for both meta-analyses), suggesting that increased mortality and worse functional outcomes were mediated by larger haematoma volumes. 
Area under the curve (SE) Model comparison p value
Versus additive Versus dominant
Mortality
Deep intracerebral haemorrhage mortality
Lobar intracerebral haemorrhage poor outcome*
Deep intracerebral haemorrhage poor outcome*
*Modifi ed Rankin scale score of 3-6 at 90 days after intracerebral haemorrhage. Warfarin use
Univariate and multivariate analysis are adjusted for principal components 1 and 2 (see webappendix p 1) to eliminate possible confounding due to population stratifi cation. There was no association between APOE ε4 and either functional outcome or mortality in patients with lobar ICH. Our study had a statistical power of more than 0·80 to detect an association between ε4 and ICH outcome or mortality with an odds ratio of more than 1·25.
We used the receiver operator characteristic method to compare predictive power for diff erent genetic models; for both mortality and disability, the additive model resulted in a better predictive performance than did the dominant or recessive models (table 6) .
There was no association between APOE genotype and outcome after deep ICH (table 5 and table 7) . Our study had a statistical power of more than 0·80 to identify associations between APOE ε2 or ε4 and deep ICH mortality and functional outcome with an odds ratio of more than 1·40.
Despite previous reports of an association between ε4 and ICH mortality, we did not replicate these fi ndings in our large multicentre dataset. We identifi ed fi ve studies [20] [21] [22] [23] [24] through our search of the published work but only two 20, 21 reported complete results of association analysis of ε2, ε4, or both with haematoma volume or post-ICH mortality or disability. In our meta-analysis of all available data (2194 patients with ICH), there was no association between ε4 and ICH outcome (odds ratio 1·08, 95% CI 0·86-1·36, p=0·52; webappendix pp 7-8). We did not identify any studies that reported the association of ε2 with ICH mortality. Similarly, no previously published report presented results of location-specifi c association analyses (ie, lobar vs deep brain), or measured disability after ICH. Therefore, no further meta-analysis with evidence from our present study could be undertaken.
Discussion
In our study, carriers of APOE ε2 who were older than 55 years and had an ICH in lobar brain regions had, on average, larger haematomas and resultant higher mortality and worse functional outcome than did non-carriers (panel).
APOE ε4 and ε2 are consistently associated with Alzheimer's disease, with the ε4 variant conferring increased risk and ε2 conferring reduced risk. 5, 25 Histopathological studies of CAA suggest that, whereas APOE ε4 has an equivalent role in CAA through enhancement of vascular amyloid-β deposition, ε2 has a diff erent eff ect, increasing vessel damage caused by β-amyloid deposition. 7 This fi nding probably accounts for the opposite eff ect of ε2 in Alzheimer's disease and CAA, and also for the results noted in this study. Consistent with this model, we reported no association between ε4 and lobar ICH volume (despite adequate statistical power). Equally, we reported no association for deep ICH, in which hypertensive vasculopathy, rather than CAA, is the major contributor to chronic small vessel damage.
Our data support the model of ICH development and growth proposed by Fisher, 26, 27 in which ICH fi rst occurs from rupture of a culprit vessel. As the blood leaks out to form a haematoma, diseased vessels in the periphery of the haematoma are injured by the haemorrhage and then rupture, causing additional leakage of blood. Individuals with ICH related to CAA who also are
Panel: Research in context
Systematic review
We searched the PubMed, Ovid, Embase, and Medline databases for studies that investigated the association of APOE with intracerebral haemorrhage volume or outcomes in human beings with the search terms "APOE", "apolipoprotein E", "e2", "e4", "ε2", "ε4", "epsilon 2", "epsilon 4", "ICH", "intracerebral hemorrhage", "cerebral bleed", "parenchymal hemorrhage", "mortality", "death", "death rate", "outcome", "disability", "dependency", "functional dependence", "functional independence", "mRS", "modifi ed Rankin Scale", "Barthel", "Barthel index", "GOS", and "Glasgow Outcome Scale". We also manually reviewed references from identifi ed reports for eligible studies. For studies that overlapped with published reports, only the most recent comprehensive results were included. We restricted our review to publications that presented complete results of association analysis of ε2, ε4, or both with haematoma volume or post-ICH mortality or disability.
Interpretation APOE ε2 is associated with larger haematoma volume and, as a result, worse outcome after lobar ICH. The associations of ε2 with ICH volume and outcome have not been investigated in previously published studies. Previous fi ndings of association between ε4 and mortality from ICH (irrespective of location) were not confi rmed in our large multicentre study and meta-analysis of 2194 individuals with ICH.
Mortality (n=456)
Poor outcome (n=456)
Univariate
Multivariate Univariate Multivariate
Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Univariate and multivariate analysis are adjusted for principal components 1 and 2 (see webappendix p 1) to eliminate possible confounding due to population stratifi cation. carriers of APOE ε2 would therefore be more likely to have severely aff ected vessels adjacent to the haemorrhage than would non-carriers, accounting for the reported association with larger haematoma volume at presentation. Thus, although both ε4 and ε2 are risk factors for original development of ICH related to CAA, only ε2 infl uences haematoma volume because of its eff ects on the severity of CAA-related vessel damage. This model might explain why ε2, but not ε4, has been associated with risk of warfarin-related ICH in the lobar brain regions in a case-control analysis. 28 We did not confi rm the results of previous studies [20] [21] [22] [23] [24] in which APOE ε4 was associated with increased in-hospital mortality after ICH. The original publications reporting this association described small cohorts and did not stratify by location of ICH. Furthermore, they applied the dominant genetic model and did joint analysis of cases of diff erent ancestry without controlling for population stratifi cation. As we showed, these factors probably led to model misspecifi cation and a reduction in statistical power. Thus, the substantially larger sample size of our study and the analytical methods that we used probably account for the discrepancy between our fi ndings and those previously reported.
We initially set our signifi cance threshold at p<0·05 because of the pre-existing evidence for a role of APOE in CAA-related ICH, and the absence of independence of analysed phenotypes (ie, haematoma volume predicts both mortality and disability after ICH). 4 However, results of ICH volume analyses for ε2 achieved genomewide signi fi cance (p<5·0×10 -⁸). The genome-wide threshold is equiva lent to the estimated Bonferroni correction for all independently testable common variants (minor allele frequency >0·01) in the human genome, and is the most conservative multiple testing adjustment threshold possible for APOE alleles. 29 Results for ε2 and lobar ICH mortality and disability (which we show to be dependent on the haematoma volume eff ect) did not surpass the genome -wide threshold, but are also signifi cant (p<5·0×10 -⁵). Our study has limitations. Haematoma volumes were measured with diff erent methods (semi-automated planimetry and ABC/2) in the diff erent phases. 16, 17 However, we believe this discrepancy is unlikely to have biased our analyses towards reporting false-positive associations, because no diff erences in minor allele frequency were noted for either ε2 or ε4 when we stratifi ed by diff erent measurement techniques (all p>0·20). Indeed, introduction of diff erent techniques might introduce random errors and reduce statistical power. We obtained clinical outcome (mortality and disability) data at 90 days by telephone interviews, which raises the possibility of recall bias. However, we provide evidence that association between ε2 and ICH outcome was mediated by the eff ect of ε2 on haematoma volume, consistent with previous histopathological studies of the severity of CAA vasculopathy in carriers of the ε2 allele. 7, 8 Finally, our samples are drawn from multiple cohorts, assembled at hospitals that serve varied populations. Diff erences might exist in local screening techniques or other procedures and could have introduced additional biases into our study. Thus, we have shown that presence of the APOE ε2 allele is associated with increased haematoma volume in lobar ICH, probably a result of the role of ε2 in the severity of vasculopathy in CAA. This genetic eff ect directly translates to eff ects on mortality and poor outcome. However, the biological mechanisms that underlie these associations and targets for therapeutic interventions are not well defi ned. 
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